The Fly

Compugen price target lowered to $8 from $12 at Oppenheimer

Oppenheimer analyst Mark Breidenbach lowered the firm’s price target on Compugen to $8 from $12 but keeps an Outperform rating on the shares. The analyst says the company missed his expectations on Q3 earnings due to higher-than-expected R&D expense, and based on the latest cash burn guidance from management, he expects Compugen’s $88.2M end-quarter cash position to sustain operations into late 2024. Breidenbach adds however that Compugen’s clinical results were accompanied by a "wealth of translational data" demonstrating successful inflammation of immunologically "cold" tumors.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More